APOE orchestrated ''molecular signatures'' in aging brain and AD - the contribution of APOE2

APOE 在衰老大脑和 AD 中精心策划了“分子特征”——APOE2 的贡献

基本信息

项目摘要

APOE (Apolipoprotein E) is part of APOE/APOC gene cluster on chromosome 19 and codes for 3 protein isoforms – APOE2, APOE3 and APOE4. APOE transports cholesterol and phospholipids in the periphery and brain. APOE isoforms differ in their lipid and receptor binding capacity and their role is associated with clearance of LDL, VLDL and chylomicrons. The inheritance of APOE4 allele increases and APOE2 decreases the risk for late onset AD (LOAD), but the mechanism is poorly understood. While APOE is involved in critical cellular functions such as oxidative processes, inflammation, glial cell and neuronal homeostasis, none of those can be dissociated from isoform specific binding, transport and delivery of cholesterol and phospholipids to different cell types. Recent reports suggest there might be a differential APOE-isoform specific effect on microglia mediated phagocytosis and function of immune receptors expressed in brain. Our preliminary data demonstrate APOE isoforms influence expression of immune receptors Dectin-1/Clec7a, Siglec1, Siglech, Oscar - involved in inflammatory response and phagocytosis. A strong support to an interconnected role for APOE and immune receptor mediated phagocytosis are our results of Multi-Dimensional Mass Spectrometry Shotgun Lipidomics of brain samples from AD patients, where we find significant differences in phospholipid molecular speciation in major phospholipid classes. We hypothesize the APOE isoform-specific effects on phagocytosis are driven by the different phospholipid composition of APOE lipid particles and/or by the differential effect of APOE isoforms on microglial transcriptome. We are proposing 3 Specific Aims to test the hypothesis: Aim 1. Establish isoform- dependent effect of APOEε2 allele on brain parenchymal and mitochondrial lipidome and transcriptome in AD patients and non-demented controls. The goal is to integrate lipid and transcriptional profiles and to reveal APOE allele controlled phenotypes and lipid molecular species for additional functional assays in SA3. Aim 2. Determine isoform- and age-dependent effect of APOE genotype on brain lipidome and transcriptome in mice expressing human APOE2, APOE3 or APOE4 isoforms. We will determine phospholipid content of native APOE in Astrocyte Conditioned media, lipid particles in brain interstitial fluid (ISF) and differences in brain parenchyma and mitochondrial lipidomes between mice expressing APOE2, APOE3 or APOE4 isoforms at 2 different ages. Aim 3. To test the effect of APOE-containing nanoparticles on Aβ phagocytosis in vitro and in vivo. The goals are to apply the knowledge about differences in lipid compositions of AD and mouse brains and to test the effect of phospholipid molecular species on microglia mediated Aβ phagocytosis and clearance of Aβ oligomeric species in in vitro and in vivo experimental systems.
载脂蛋白E(Apolipoprotein E,APOE)是位于19号染色体上的APOE/APOC基因簇的一部分,编码3种蛋白质 同种型-APOE2、APOE3和APOE4。APOE在外周转运胆固醇和磷脂, 个脑袋APOE亚型在脂质和受体结合能力方面不同,它们的作用与清除有关 低密度脂蛋白极低密度脂蛋白和乳糜微粒APOE 4等位基因的遗传增加,APOE 2降低了 迟发性AD(LOAD),但其机制知之甚少。虽然APOE参与了关键的细胞 功能,如氧化过程,炎症,神经胶质细胞和神经元的稳态,没有一个可以被 与胆固醇和磷脂到不同细胞同种型特异性结合、转运和递送分离 类型最近的报道表明,可能存在差异APOE亚型特异性作用于小胶质细胞介导的 吞噬作用和脑中表达的免疫受体的功能。我们的初步数据表明, 同种型影响免疫受体Dectin-1/Clec7a、Siglec1、Siglech、Oscar的表达, 炎症反应和吞噬作用。对APOE和免疫的相互作用的有力支持 受体介导的吞噬作用是我们的多维质谱鸟枪脂质组学的结果, 从AD患者的大脑样本中,我们发现磷脂分子形态的显着差异, 主要的磷脂类。我们假设APOE亚型对吞噬作用的特异性作用是由以下因素驱动的: APOE脂质颗粒的不同磷脂组成和/或APOE同种型的差异效应 在小胶质细胞转录组上我们提出了3个具体目标来检验假设:目标1。建立亚型- AD患者APOE ε 2等位基因对脑实质和线粒体脂质组及转录组依赖性影响 患者和非痴呆对照。目标是整合脂质和转录谱,并揭示 APOE等位基因控制的表型和脂质分子种类,用于SA3中的其他功能测定。目标2. 确定APOE基因型对脑脂质组和转录组的亚型和年龄依赖性影响, 表达人APOE2、APOE3或APOE4同种型的小鼠。我们将测定 星形胶质细胞条件培养基中的天然APOE,脑间质液(ISF)中的脂质颗粒和脑内 表达APOE2、APOE3或APOE4亚型的小鼠之间的实质和线粒体脂质体的差异 不同年龄目标3.检测载脂蛋白E纳米粒对体外A β吞噬功能的影响 和体内。目的是应用有关AD和小鼠脂质组成差异的知识, 并测试磷脂分子种类对小胶质细胞介导的A β吞噬作用的影响, 体外和体内实验系统中A β寡聚物的清除。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Genome-wide alteration of histone methylation profiles associated with cognitive changes in response to developmental arsenic exposure in mice.
  • DOI:
    10.1016/j.toxrep.2022.03.008
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Fitz NF;Barchowsky A;Koldamova R;Lefterov I
  • 通讯作者:
    Lefterov I
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RADOSVETA KOLDAMOVA其他文献

RADOSVETA KOLDAMOVA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RADOSVETA KOLDAMOVA', 18)}}的其他基金

The interplay between Tau and ncRNAs – genomic and epigenomic clues to early AD pathogenesis
Tau 和 ncRNA 之间的相互作用 — 早期 AD 发病机制的基因组和表观基因组线索
  • 批准号:
    10447273
  • 财政年份:
    2022
  • 资助金额:
    $ 44.06万
  • 项目类别:
The interplay between Tau and ncRNAs – genomic and epigenomic clues to early AD pathogenesis
Tau 和 ncRNA 之间的相互作用 — 早期 AD 发病机制的基因组和表观基因组线索
  • 批准号:
    10634661
  • 财政年份:
    2022
  • 资助金额:
    $ 44.06万
  • 项目类别:
ncRNAs in plasma EVs of AD patients and their discriminatory power as biomarkers
AD 患者血浆 EV 中的 ncRNA 及其作为生物标志物的区分能力
  • 批准号:
    10532000
  • 财政年份:
    2022
  • 资助金额:
    $ 44.06万
  • 项目类别:
APOE Orchestrated Molecular Signatures in Aging Brain and AD-the Contribution of APOE2
APOE 在衰老大脑和 AD 中精心设计的分子特征——APOE2 的贡献
  • 批准号:
    10450775
  • 财政年份:
    2018
  • 资助金额:
    $ 44.06万
  • 项目类别:
APOE Orchestrated Molecular Signatures in Aging Brain and AD-the Contribution of APOE2
APOE 在衰老大脑和 AD 中精心设计的分子特征——APOE2 的贡献
  • 批准号:
    10170188
  • 财政年份:
    2018
  • 资助金额:
    $ 44.06万
  • 项目类别:
Epigenetic and phenotypic effects of arsenic: impacts on cognition and AD
砷的表观遗传和表型效应:对认知和 AD 的影响
  • 批准号:
    8755745
  • 财政年份:
    2014
  • 资助金额:
    $ 44.06万
  • 项目类别:
LXR and human ApoE isoform effects on AD phenotype: in vitro and in vivo models
LXR 和人 ApoE 亚型对 AD 表型的影响:体外和体内模型
  • 批准号:
    8103681
  • 财政年份:
    2011
  • 资助金额:
    $ 44.06万
  • 项目类别:
LXR and human ApoE isoform effects on AD phenotype: in vitro and in vivo models
LXR 和人 ApoE 亚型对 AD 表型的影响:体外和体内模型
  • 批准号:
    8484324
  • 财政年份:
    2011
  • 资助金额:
    $ 44.06万
  • 项目类别:
LXR and human ApoE isoform effects on AD phenotype: in vitro and in vivo models
LXR 和人 ApoE 亚型对 AD 表型的影响:体外和体内模型
  • 批准号:
    8277207
  • 财政年份:
    2011
  • 资助金额:
    $ 44.06万
  • 项目类别:
LXR and human ApoE isoform effects on AD phenotype: in vitro and in vivo models
LXR 和人 ApoE 亚型对 AD 表型的影响:体外和体内模型
  • 批准号:
    8850760
  • 财政年份:
    2011
  • 资助金额:
    $ 44.06万
  • 项目类别:

相似海外基金

Environmental copper exposure and its impact on microglial Abeta clearance
环境铜暴露及其对小胶质细胞 Abeta 清除的影响
  • 批准号:
    8757425
  • 财政年份:
    2014
  • 资助金额:
    $ 44.06万
  • 项目类别:
Development of Novel Therapies for AD Targeting Abeta Clearance
针对 Abeta 清除的 AD 新型疗法的开发
  • 批准号:
    8820188
  • 财政年份:
    2014
  • 资助金额:
    $ 44.06万
  • 项目类别:
Development of Novel Therapies for AD Targeting Abeta Clearance
针对 Abeta 清除的 AD 新型疗法的开发
  • 批准号:
    9040023
  • 财政年份:
    2014
  • 资助金额:
    $ 44.06万
  • 项目类别:
Environmental copper exposure and its impact on microglial Abeta clearance
环境铜暴露及其对小胶质细胞 Abeta 清除的影响
  • 批准号:
    8930156
  • 财政年份:
    2014
  • 资助金额:
    $ 44.06万
  • 项目类别:
Caloric restriction and Alzheimers ABeta clearance pathway
热量限制和阿尔茨海默病 Aβ 清除途径
  • 批准号:
    8897941
  • 财政年份:
    2013
  • 资助金额:
    $ 44.06万
  • 项目类别:
Caloric restriction and Alzheimers ABeta clearance pathway
热量限制和阿尔茨海默病 Aβ 清除途径
  • 批准号:
    8411069
  • 财政年份:
    2013
  • 资助金额:
    $ 44.06万
  • 项目类别:
Caloric restriction and Alzheimers ABeta clearance pathway
热量限制和阿尔茨海默病 Aβ 清除途径
  • 批准号:
    8713897
  • 财政年份:
    2013
  • 资助金额:
    $ 44.06万
  • 项目类别:
The role of human ApoE in soluble ABeta clearance through the LDLR in vivo
人 ApoE 在体内通过 LDLR 清除可溶性 Aβ 中的作用
  • 批准号:
    7752282
  • 财政年份:
    2009
  • 资助金额:
    $ 44.06万
  • 项目类别:
The role of human ApoE in soluble ABeta clearance through the LDLR in vivo
人 ApoE 在体内通过 LDLR 清除可溶性 Aβ 中的作用
  • 批准号:
    8090296
  • 财政年份:
    2009
  • 资助金额:
    $ 44.06万
  • 项目类别:
Development of therapeutics for dementia targeting Abeta clearance
开发针对 Abeta 清除的痴呆疗法
  • 批准号:
    20590697
  • 财政年份:
    2008
  • 资助金额:
    $ 44.06万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了